Sign In
Buy SCPH
$5.67
+0 (+0%)
At Close: Jan 06, 2026
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
04:01pm, Wednesday, 13'th Nov 2024
Generated 3Q 2024 net FUROSCIX ® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
04:01pm, Wednesday, 06'th Nov 2024
Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024
08:30am, Tuesday, 15'th Oct 2024
Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease Webinar to focus on a nephrologist's perspective
Does scPharmaceuticals (SCPH) Have the Potential to Rally 291.9% as Wall Street Analysts Expect?
10:55am, Friday, 16'th Aug 2024
The mean of analysts' price targets for scPharmaceuticals (SCPH) points to a 291.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo
scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript
05:10am, Thursday, 15'th Aug 2024
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP, Commercial Rachael Nokes
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
06:21pm, Wednesday, 14'th Aug 2024
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.44 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.36 per share a year ago.
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
04:01pm, Wednesday, 14'th Aug 2024
Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
09:48am, Monday, 12'th Aug 2024
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
06:05am, Monday, 12'th Aug 2024
scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
06:04am, Monday, 12'th Aug 2024
FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
06:02am, Monday, 12'th Aug 2024
SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative op
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
06:00am, Monday, 12'th Aug 2024
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have th
7 Short-Squeeze Stocks That Could Beat Down the Bears
11:57am, Monday, 15'th Jul 2024
Short-squeeze stocks represent one of the boldest forms of contrarianism available. Simply put, it's a showdown between the bears that are attempting to profit from the downturn of a public enterprise
scPharmaceuticals to Present at the Jefferies Global Healthcare Conference
04:01pm, Wednesday, 29'th May 2024
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi
scPharmaceuticals Inc. (SCPH) Q1 2024 Earnings Call Transcript
07:02pm, Tuesday, 14'th May 2024
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP of Commercial Rachael Nokes -
